If you own an independent pharmacy, you already know what a Pharmacy Benefit Manager is. You live with the consequences of their decisions every day - the reimbursement rates that sometimes come in below what you paid for the drug, the audits that arrive without warning, and the network exclusions that happen when a PBM decides to steer patients to a pharmacy it owns.
What you may not have fully processed yet: Congress passed significant PBM reform in February 2026 as part of the Consolidated Appropriations Act of 2026. Some of what changed is immediate. Most of the major provisions take effect in 2028 and 2029. But there are things you should be doing right now to position your pharmacy for what is coming.
This is a breakdown of what changed, what it means, and what to do with it.
First, the Quick Version of Why This Matters
PBMs - Pharmacy Benefit Managers - are the companies that sit between drug manufacturers and the pharmacies where patients pick up their prescriptions. They negotiate drug prices with manufacturers, set the reimbursement rates that pharmacies receive, and decide which pharmacies get included in insurance networks.
Three companies - CVS Caremark, Express Scripts, and OptumRx - control roughly 80 percent of all U.S. prescription claims. Each of those three companies also owns pharmacy chains. When they can steer patients away from independent pharmacies and toward their own retail operations, they do. The system has been creating an obvious conflict of interest for decades, and independent pharmacies have been losing ground because of it.
The 2026 reform law is the most significant federal intervention in PBM practices in the history of the industry, according to legal analysts at Ropes and Gray. Here is what it actually does.
The Four Changes That Matter Most
1. "Any Willing Pharmacy" requirements for Medicare Part D networks
This is the most immediately meaningful change for independent pharmacies. Beginning now - not in 2028, but now - Medicare Part D plans must allow any pharmacy that meets their standard contract terms to participate in their network.
This means: if you have been excluded from a Part D plan's network because the PBM that runs it preferred to keep patients flowing to its own pharmacies, that practice is now prohibited. You can challenge exclusions that do not have a legitimate, documented, plan-related reason.
Barclay Damon's analysis notes that the new standard contract terms must be "reasonable and relevant" - which gives independent pharmacies a basis to push back on exclusions that appear designed to drive business to PBM-affiliated chains.
2. Delinking PBM compensation from drug prices
Beginning January 1, 2028, PBMs that provide services to Medicare Part D plans will no longer be able to tie their own compensation to drug prices or rebate arrangements. Instead, they will be paid a "bona fide service fee" based on the fair market value of services they actually provide.
Why this matters: today, PBMs profit more when the drugs they place on formularies have higher list prices (because their rebates are calculated as a percentage of that price). This creates a perverse incentive to favor expensive brand-name drugs even when cheaper generics are available. Delinking their pay from drug prices is designed to remove that incentive.
For your pharmacy specifically: this does not change your reimbursement rate directly. But over time, a formulary driven less by rebate optimization should create a more rational pricing environment for the drugs you dispense.
3. 100 percent rebate pass-through to employer health plans
PBMs that serve employer-sponsored health plans are now required to pass through 100 percent of the rebates and fees they receive from drug manufacturers to the employer.
Previously, PBMs could keep a portion of those rebates - which is where a significant chunk of their revenue came from. This provision, combined with new transparency requirements from the Department of Labor, is intended to force employer plans to understand the actual economics of their pharmacy benefits.
For independent pharmacy owners, the downstream effect is indirect but real: as employers get clearer visibility into where their drug spending goes, they will have more incentive to push for pharmacy network structures that compete on price and service rather than on PBM-owned convenience.
4. New transparency and reporting requirements
PBMs are now required to provide new disclosures to the plans they serve, covering how they are compensated, what audits they conduct, and how network decisions are made. The Department of Labor issued a proposed rule in January 2026 requiring additional disclosure in the self-insured employer market.
Translation for pharmacy owners: the audit practices that have long felt arbitrary and opaque are now subject to documentation requirements. If a PBM audits your pharmacy, that audit process itself is now more regulated.
What This Looks Like on a Timeline
The "Any Willing Pharmacy" rule is in effect now. The transparency requirements are in effect now. PBM compensation delinking begins January 1, 2028. Full rebate pass-through requirements take full effect in 2028-2029.
The reason for the delay is that PBMs negotiated extended implementation periods during the legislative process. The industry did not go quietly. But the framework is locked in.
What to Do Right Now
Audit your current network participation. Make a list of every Part D plan and employer plan operating in your area. Are you included? If you have been excluded from a plan without a clear reason tied to your performance or qualifications, the new "Any Willing Pharmacy" rule gives you standing to request inclusion. Contact your state pharmacy association - most have legal resources to help members pursue network access disputes.
Review your current PBM contracts. Some of the most punishing terms for independent pharmacies are buried in contract language that was written when there was no legal pressure to make them fair. With reform coming, some PBMs may be more open to renegotiation than they were previously. It is worth a conversation.
Document everything. If a PBM audits you over the next two years, the audit process is now more regulated than it used to be. Keep detailed records of every audit request, every response, and every outcome. If the audit seems retaliatory or exceeds the scope of what is contractually permitted, the new transparency rules give you grounds for a formal complaint.
Talk to your state pharmacy board. State-level PBM reform efforts are running alongside the federal changes. Many states passed additional protections in 2024 and 2025. Your state may have even more specific tools available to you.
The Honest Bottom Line
The 2026 law does not fix everything. Forbes reported in March 2026 that independent pharmacy closures continue, and the financial model remains under serious strain while we wait for the major provisions to take effect.
But the legal architecture has shifted in your favor for the first time in decades. The "Any Willing Pharmacy" rule alone is actionable right now. The transparency requirements mean the audit games are harder to play invisibly. And the delinking provision, when it takes effect, removes a structural incentive that has cost independent pharmacies billions in steered business.
Use the window between now and 2028 to prepare: get into networks you have been excluded from, renegotiate contracts where you can, and build the documentation practices that will protect you through the transition.
Sources: Barclay Damon - PBM Reforms Enacted in 2026; Ropes and Gray - Year of PBM Reform; Drug Topics - What's Ahead in 2026 for Independent Pharmacies; Datascan Pharmacy - Biggest Challenges for Independent Pharmacy; Forbes - The Pharmacy Business Model Is Breaking; Mintz - Congress Passes Landmark PBM Reform